PlainRecalls
FDA Devices Moderate Class II Ongoing

HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.

Reported: December 1, 2021 Initiated: October 13, 2021 #Z-0276-2022

Product Description

HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.

Reason for Recall

The firm has received customer reports of performance issues with the affected lot, including increased imprecision, out of range quality controls, and prolonged sample results. If quality controls are not performed or do not pass for each vial of reagent, there is a potential risk of reporting an erroneous result.

Details

Units Affected
5828 kits (310 US)
Distribution
Worldwide distribution - US Nationwide distribution in the states of AZ, CA, IA, IL, KS, ME, MI, NC, NY, OK, SC, and VA. The countries of Canada, Chile, China, Costa Rica, Italy, Japan, and South Korea. ***Updated 3/3/22*** Expansion includes states of IN, MN, and NC.
Location
Bedford, MA

Frequently Asked Questions

What product was recalled?
HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.. Recalled by Instrumentation Laboratory. Units affected: 5828 kits (310 US).
Why was this product recalled?
The firm has received customer reports of performance issues with the affected lot, including increased imprecision, out of range quality controls, and prolonged sample results. If quality controls are not performed or do not pass for each vial of reagent, there is a potential risk of reporting an erroneous result.
Which agency issued this recall?
This recall was issued by the FDA Devices on December 1, 2021. Severity: Moderate. Recall number: Z-0276-2022.